<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02104752</url>
  </required_header>
  <id_info>
    <org_study_id>2013-121701</org_study_id>
    <nct_id>NCT02104752</nct_id>
  </id_info>
  <brief_title>Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia</brief_title>
  <official_title>Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Greater Los Angeles Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Theravalues, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Greater Los Angeles Healthcare System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to test whether curcumin nanoparticles will improve behavioral
      measures and biomarkers of cognition and neuroplasticity in patients with schizophrenia who
      are already receiving a stable dose of antipsychotic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will use a formulation of curcumin with high bioavailability that possesses
      a pharmacokinetic profile expected to exert biological effects. Specifically, 36 subjects
      will be enrolled in the double-blind randomized controlled trial. They will be randomized to
      curcumin or placebo for 8 weeks. At baseline, and 4 and 8 weeks, subjects will receive
      assessments of neurocognition (e.g., processing speed, attention and vigilance, working
      memory, learning, reasoning and problem solving), social cognition, EEG biomarkers (e.g.,
      visual cortical plasticity and mismatch negativity), a serum marker of neurogenesis (BDNF
      levels), and clinical symptoms (positive and negative symptoms). At weeks 2 and 6 subjects
      will return for additional safety (e.g., vitals, side effects, akathisia) and medication
      adherence assessments. Improvement on the primary outcome measure (MATRICS Consensus
      Cognitive Battery), as well as secondary outcome measures, will be compared between
      participants randomized to placebo versus curcumin. The results of this study will establish
      whether curcumin is a viable adjunctive agent for future larger clinical trials.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB)</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>This battery was developed as part of the National Institute of Mental Health (NIMH) sponsored Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Initiative to assess cognition in clinical trials of cognition enhancing drugs. The MCCB comprises 10 tests that assess 7 cognitive domains (speed of processing, verbal memory, visual memory, working memory, reasoning and problem solving, attention/vigilance, and social cognition). The MCCB takes approximately 65 minutes to administer and provides age and gender-corrected normed T-scores, including a global composite score and cognitive domain scores. The range of T-scores is between 0 to 100 with a mean of 50. Higher scores indicate better overall cognitive functioning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electroencephalogram (EEG) Mismatch Negativity Paradigm (MMN)</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>A passive attention auditory oddball paradigm will be used to assess MMN. For MMN, difference waves generated by subtracting the standard from deviant event related potentials (ERP) will be analyzed. The specific electrodes used to examine each component will be chosen based on maximal activity seen by inspection of the topographical maps. More negative values indicate a larger (i.e., better) MMN response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Derived Neurotrophic Factor (BDNF)</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>Serum will be collected at baseline, 4 weeks, and 8 weeks. BDNF concentrations will be quantified by enzyme-linked immunosorbent assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Psychiatric Rating Scale (BPRS)</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>The Brief Psychiatric Rating Scale (BPRS) will be the primary measure for assessing positive symptoms. We will be using the UCLA expanded 24-item version of the scale. The total score ranges from 24-168, with lower scores being better (i.e., less symptomatology).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Clinical Assessment Interview for Negative Symptoms (CAINS)</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>The Clinical Assessment Interview for Negative Symptoms (CAINS) will be used to assess negative symptoms. This scale is comprised of 9 items that rate motivation and pleasure symptoms and 4 items that rate expression symptoms.
We are reporting the motivation subscale. The total score can range from 0-36 (summed over the 9 items), with lower scores being better (i.e., less symptomatology).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Cognition</condition>
  <condition>Psychosis</condition>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Curcumin capsules (Theracurmin formulation of curcumin nanoparticles). Subjects randomized to curcumin will receive 360 mg/day (divided into twice daily oral doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo, 2 capsules twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>360 mg/day (divided into twice daily oral doses)</description>
    <arm_group_label>Curcumin</arm_group_label>
    <other_name>Theracurmin</other_name>
    <other_name>Curcumin nanoparticles</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive, matched placebo (&quot;Sugar Pill&quot;)</description>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-5 diagnosis of schizophrenia

          -  age 18 - 65 years

          -  understand spoken English sufficiently to comprehend testing procedures

          -  corrected vision of at least 20/30

          -  currently prescribed an antipsychotic medication

        Exclusion Criteria:

          -  clinically significant neurological disease determined by medical history (e.g.,
             epilepsy)

          -  history of serious head injury (i.e., loss of consciousness &gt; 1 hr., no
             neuropsychological sequelae, no cognitive rehabilitation post head injury)

          -  sedatives or benzodiazepines within 12 hrs of testing

          -  any psychiatric hospitalization within 3 months prior to study participation

          -  behaviors suggesting any potential danger to self or others within 6 months prior to
             study participation

          -  antipsychotic dose change more than 50% over the 3 months prior to study participation

          -  acute medical problems or untreated chronic medical conditions within 3 months prior
             to study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen R Marder, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Greater Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan K Wynn, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Greater Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael C Davis, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Greater Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Greater Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hurley LL, Akinfiresoye L, Nwulia E, Kamiya A, Kulkarni AA, Tizabi Y. Antidepressant-like effects of curcumin in WKY rat model of depression is associated with an increase in hippocampal BDNF. Behav Brain Res. 2013 Feb 15;239:27-30. doi: 10.1016/j.bbr.2012.10.049. Epub 2012 Nov 8.</citation>
    <PMID>23142609</PMID>
  </reference>
  <reference>
    <citation>Dong S, Zeng Q, Mitchell ES, Xiu J, Duan Y, Li C, Tiwari JK, Hu Y, Cao X, Zhao Z. Curcumin enhances neurogenesis and cognition in aged rats: implications for transcriptional interactions related to growth and synaptic plasticity. PLoS One. 2012;7(2):e31211. doi: 10.1371/journal.pone.0031211. Epub 2012 Feb 16.</citation>
    <PMID>22359574</PMID>
  </reference>
  <reference>
    <citation>Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K, Morimoto T. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011;34(5):660-5.</citation>
    <PMID>21532153</PMID>
  </reference>
  <reference>
    <citation>Shamsi S, Lau A, Lencz T, Burdick KE, DeRosse P, Brenner R, Lindenmayer JP, Malhotra AK. Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res. 2011 Mar;126(1-3):257-64. doi: 10.1016/j.schres.2010.08.007. Epub 2010 Sep 15.</citation>
    <PMID>20828991</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 1, 2014</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <results_first_submitted>October 30, 2017</results_first_submitted>
  <results_first_submitted_qc>April 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 15, 2019</results_first_posted>
  <last_update_submitted>April 23, 2019</last_update_submitted>
  <last_update_submitted_qc>April 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VA Greater Los Angeles Healthcare System</investigator_affiliation>
    <investigator_full_name>Michael C. Davis, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>Curcumin</keyword>
  <keyword>Turmeric</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Cognition</keyword>
  <keyword>Psychosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Curcumin</title>
          <description>Curcumin capsules (Theracurmin formulation of curcumin nanoparticles). Subjects randomized to curcumin will receive 360 mg/day (divided into twice daily oral doses).
Curcumin: 360 mg/day (divided into twice daily oral doses)</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Matched placebo, 2 capsules twice daily.
Placebo: Inactive, matched placebo (&quot;Sugar Pill&quot;)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Weight gain; unrelated anxiety</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Curcumin</title>
          <description>Curcumin capsules (Theracurmin formulation of curcumin nanoparticles). Subjects randomized to curcumin will receive 360 mg/day (divided into twice daily oral doses).
Curcumin: 360 mg/day (divided into twice daily oral doses)</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Matched placebo, 2 capsules twice daily.
Placebo: Inactive, matched placebo (&quot;Sugar Pill&quot;)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.1" spread="9.6"/>
                    <measurement group_id="B2" value="50.9" spread="10.6"/>
                    <measurement group_id="B3" value="50.5" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB)</title>
        <description>This battery was developed as part of the National Institute of Mental Health (NIMH) sponsored Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Initiative to assess cognition in clinical trials of cognition enhancing drugs. The MCCB comprises 10 tests that assess 7 cognitive domains (speed of processing, verbal memory, visual memory, working memory, reasoning and problem solving, attention/vigilance, and social cognition). The MCCB takes approximately 65 minutes to administer and provides age and gender-corrected normed T-scores, including a global composite score and cognitive domain scores. The range of T-scores is between 0 to 100 with a mean of 50. Higher scores indicate better overall cognitive functioning.</description>
        <time_frame>Baseline, Week 4, Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Curcumin</title>
            <description>Curcumin capsules (Theracurmin formulation of curcumin nanoparticles). Subjects randomized to curcumin will receive 360 mg/day (divided into twice daily oral doses).
Curcumin: 360 mg/day (divided into twice daily oral doses)</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Matched placebo, 2 capsules twice daily.
Placebo: Inactive, matched placebo (&quot;Sugar Pill&quot;)</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB)</title>
          <description>This battery was developed as part of the National Institute of Mental Health (NIMH) sponsored Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Initiative to assess cognition in clinical trials of cognition enhancing drugs. The MCCB comprises 10 tests that assess 7 cognitive domains (speed of processing, verbal memory, visual memory, working memory, reasoning and problem solving, attention/vigilance, and social cognition). The MCCB takes approximately 65 minutes to administer and provides age and gender-corrected normed T-scores, including a global composite score and cognitive domain scores. The range of T-scores is between 0 to 100 with a mean of 50. Higher scores indicate better overall cognitive functioning.</description>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6" spread="15.1"/>
                    <measurement group_id="O2" value="32.9" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="14.5"/>
                    <measurement group_id="O2" value="33.8" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" spread="14.5"/>
                    <measurement group_id="O2" value="33.9" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Electroencephalogram (EEG) Mismatch Negativity Paradigm (MMN)</title>
        <description>A passive attention auditory oddball paradigm will be used to assess MMN. For MMN, difference waves generated by subtracting the standard from deviant event related potentials (ERP) will be analyzed. The specific electrodes used to examine each component will be chosen based on maximal activity seen by inspection of the topographical maps. More negative values indicate a larger (i.e., better) MMN response.</description>
        <time_frame>Baseline, Week 4, Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Curcumin</title>
            <description>Curcumin capsules (Theracurmin formulation of curcumin nanoparticles). Subjects randomized to curcumin will receive 360 mg/day (divided into twice daily oral doses).
Curcumin: 360 mg/day (divided into twice daily oral doses)</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Matched placebo, 2 capsules twice daily.
Placebo: Inactive, matched placebo (&quot;Sugar Pill&quot;)</description>
          </group>
        </group_list>
        <measure>
          <title>Electroencephalogram (EEG) Mismatch Negativity Paradigm (MMN)</title>
          <description>A passive attention auditory oddball paradigm will be used to assess MMN. For MMN, difference waves generated by subtracting the standard from deviant event related potentials (ERP) will be analyzed. The specific electrodes used to examine each component will be chosen based on maximal activity seen by inspection of the topographical maps. More negative values indicate a larger (i.e., better) MMN response.</description>
          <units>microVolts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="2.16"/>
                    <measurement group_id="O2" value="-1.84" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.15" spread="1.47"/>
                    <measurement group_id="O2" value="-1.99" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.15" spread="1.66"/>
                    <measurement group_id="O2" value="-1.68" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brain Derived Neurotrophic Factor (BDNF)</title>
        <description>Serum will be collected at baseline, 4 weeks, and 8 weeks. BDNF concentrations will be quantified by enzyme-linked immunosorbent assay.</description>
        <time_frame>Baseline, Week 4, Week 8</time_frame>
        <population>Participant dropped at the 8 week follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Curcumin</title>
            <description>Curcumin capsules (Theracurmin formulation of curcumin nanoparticles). Subjects randomized to curcumin will receive 360 mg/day (divided into twice daily oral doses).
Curcumin: 360 mg/day (divided into twice daily oral doses)</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Matched placebo, 2 capsules twice daily.
Placebo: Inactive, matched placebo (&quot;Sugar Pill&quot;)</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Derived Neurotrophic Factor (BDNF)</title>
          <description>Serum will be collected at baseline, 4 weeks, and 8 weeks. BDNF concentrations will be quantified by enzyme-linked immunosorbent assay.</description>
          <population>Participant dropped at the 8 week follow-up</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11416" spread="10067"/>
                    <measurement group_id="O2" value="14227" spread="9371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15395" spread="11065"/>
                    <measurement group_id="O2" value="13288" spread="10565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14828" spread="12876"/>
                    <measurement group_id="O2" value="10219" spread="8571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Psychiatric Rating Scale (BPRS)</title>
        <description>The Brief Psychiatric Rating Scale (BPRS) will be the primary measure for assessing positive symptoms. We will be using the UCLA expanded 24-item version of the scale. The total score ranges from 24-168, with lower scores being better (i.e., less symptomatology).</description>
        <time_frame>Baseline, Week 4, Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Curcumin</title>
            <description>Curcumin capsules (Theracurmin formulation of curcumin nanoparticles). Subjects randomized to curcumin will receive 360 mg/day (divided into twice daily oral doses).
Curcumin: 360 mg/day (divided into twice daily oral doses)</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Matched placebo, 2 capsules twice daily.
Placebo: Inactive, matched placebo (&quot;Sugar Pill&quot;)</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Psychiatric Rating Scale (BPRS)</title>
          <description>The Brief Psychiatric Rating Scale (BPRS) will be the primary measure for assessing positive symptoms. We will be using the UCLA expanded 24-item version of the scale. The total score ranges from 24-168, with lower scores being better (i.e., less symptomatology).</description>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="7.7"/>
                    <measurement group_id="O2" value="38.1" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" spread="5.7"/>
                    <measurement group_id="O2" value="37.9" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="8.8"/>
                    <measurement group_id="O2" value="37.1" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Clinical Assessment Interview for Negative Symptoms (CAINS)</title>
        <description>The Clinical Assessment Interview for Negative Symptoms (CAINS) will be used to assess negative symptoms. This scale is comprised of 9 items that rate motivation and pleasure symptoms and 4 items that rate expression symptoms.
We are reporting the motivation subscale. The total score can range from 0-36 (summed over the 9 items), with lower scores being better (i.e., less symptomatology).</description>
        <time_frame>Baseline, Week 4, Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Curcumin</title>
            <description>Curcumin capsules (Theracurmin formulation of curcumin nanoparticles). Subjects randomized to curcumin will receive 360 mg/day (divided into twice daily oral doses).
Curcumin: 360 mg/day (divided into twice daily oral doses)</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Matched placebo, 2 capsules twice daily.
Placebo: Inactive, matched placebo (&quot;Sugar Pill&quot;)</description>
          </group>
        </group_list>
        <measure>
          <title>The Clinical Assessment Interview for Negative Symptoms (CAINS)</title>
          <description>The Clinical Assessment Interview for Negative Symptoms (CAINS) will be used to assess negative symptoms. This scale is comprised of 9 items that rate motivation and pleasure symptoms and 4 items that rate expression symptoms.
We are reporting the motivation subscale. The total score can range from 0-36 (summed over the 9 items), with lower scores being better (i.e., less symptomatology).</description>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="6.8"/>
                    <measurement group_id="O2" value="16.0" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="7.5"/>
                    <measurement group_id="O2" value="16.2" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="6.2"/>
                    <measurement group_id="O2" value="17.9" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Curcumin</title>
          <description>Curcumin capsules (Theracurmin formulation of curcumin nanoparticles). Subjects randomized to curcumin will receive 360 mg/day (divided into twice daily oral doses).
Curcumin: 360 mg/day (divided into twice daily oral doses)</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Matched placebo, 2 capsules twice daily.
Placebo: Inactive, matched placebo (&quot;Sugar Pill&quot;)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan K. Wynn, Ph.D.</name_or_title>
      <organization>VA Greater Los Angeles Healthcare System/UCLA</organization>
      <phone>(310) 478-3711 ext 44957</phone>
      <email>jkwynn@ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

